C18orf25

Across TCGA pan-cancer cohorts, C18orf25 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C18orf25 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C18orf25 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated C18orf25 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where C18orf25 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.109	0.825	.004	15	view →
LUAD	OS	Tertile	III,IV	1.000	0.356	.020	5	view →
HNSC	OS	Median	IV	0.585	0.811	.013	4	view →
GBM	OS	Quartile	All	0.678	0.973	.018	3	view →
CCRCC	DFS	Quartile	All	0.847	0.966	.024	3	view →
LSCC	DFS	Tertile	II,III,IV	0.876	0.499	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C18orf25–PDAC (OS)

Open the PDAC breakdown →